Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike.
Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, Winstone H, Pickering S, Galao RP, Lista MJ, Jimenez-Guardeno JM, Laing AG, Wu Y, Joseph M, Muir L, Ng WM, Duyvesteyn HME, Zhao Y, Bowden TA, Shankar-Hari M, Rosa A, Cherepanov P, McCoy LE, Hayday AC, Neil SJD, Malim MH, Doores KJ.
Graham C, et al.
bioRxiv [Preprint]. 2021 Feb 3:2021.02.03.429355. doi: 10.1101/2021.02.03.429355.
bioRxiv. 2021.
PMID: 33564766
Free PMC article.
Updated.
Preprint.
To fully understand how these mutations affect the antigenicity of Spike, we have isolated and characterized neutralizing antibodies targeting epitopes beyond the already identified RBD epitopes. Using recombinant Spike as a sorting bait, we isolated >100 Spike-reactive …
To fully understand how these mutations affect the antigenicity of Spike, we have isolated and characterized neutralizing antibodies targeti …